Wave Life Sciences, Inc.
No enriched coverage for $WVE in the last 7 days.
No SEC Form 4 filings for $WVE in the last 30 days.
See all $WVE insider activity →H.C. Wainwright reiterated a Buy rating on Wave Life Sciences (WVE) with a $13 price target. The FDA aligned on a single trial for WVE-006, validating prior data. Wave reported Q2 2026 losses of $0.34 per share, missing revenue expectations at $2.3M. The company completed redomiciliation to Delaware, and JPMorgan resumed coverage with a Neutral rating.
Wave Life Sciences (WVE) reported FDA alignment on a single two-year trial for WVE-006 in AATD, with a one-year interim analysis for potential accelerated approval. FDA also supports the company's current LC-MS assay.
Wave Life Sciences (WVE) reported FDA alignment on a registrational pathway for WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year trial with a one-year interim analysis for potential accelerated approval. WVE-006 aims to treat both lung and liver manifestations of AATD with infrequent subcutaneous dosing. Wave expects to share data from the RestorAATion-2 trial in Q4 2026.
Recent WVE coverage spans earnings, regulation and technology.
Negative earnings surprise and cash burn likely pressure the stock.
Regulatory alignment reduces uncertainty and may boost the stock.
Positive regulatory alignment may lift the stock as investors price in a clearer path to approval.
Positive cash inflow and potential future upside from the GSK collaboration.
The trial start provides fresh clinical data that could de‑risk the obesity program and move the stock.
AlphAI scores every news story that mentions WVE with an AI model for sentiment and relevance, and aggregates insider trades from Wave Life Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating on Wave Life Sciences (WVE) with a $13 price target. The FDA aligned on a single trial for WVE-006, validating prior data. Wave reported Q2 2026 losses of $0.34 per share, missing revenue expectations at $2.3M. The company completed redomiciliation to Delaware, and JPMorgan resumed coverage with a Neutral rating.
2 min readWave Life Sciences (WVE) reported FDA alignment on a single two-year trial for WVE-006 in AATD, with a one-year interim analysis for potential accelerated approval. FDA also supports the company's current LC-MS assay.
2 min readWave Life Sciences (WVE) reported FDA alignment on a registrational pathway for WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year trial with a one-year interim analysis for potential accelerated approval. WVE-006 aims to treat both lung and liver manifestations of AATD with infrequent subcutaneous dosing. Wave expects to share data from the RestorAATion-2 trial in Q4 2026.
2 min readWave Life Sciences (WVE) announced that GSK selected a siRNA program for further development, triggering a $12M milestone payment. Wave may receive up to $375M in additional milestones and royalties per program. Three other programs are advancing under their collaboration.
1 min readWave Life Sciences (WVE) initiated a Phase 2a trial for WVE-007, its investigational GalNAc-siRNA, in combination with tirzepatide for obesity treatment. The trial aims to evaluate the combination therapy's efficacy in adults with obesity and type 2 diabetes. Wave also plans to initiate a maintenance trial for WVE-007 in the second half of 2026. Preclinical data suggest WVE-007 could enhance fat loss and preserve muscle when combined with GLP-1 therapies.
2 min readWave Life Sciences, Inc. (NASDAQ: WVE) said it completed its redomiciliation to Delaware via a Singapore scheme of arrangement. After Aug. 7, 2026 close, Wave exchanged all issued ordinary shares one-for-one for newly issued Delaware common stock. The equity continues under WVE and the new shares began trading on Nasdaq Aug. 10, 2026.
3 min readWVE (WVE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Indemnification and Advancement Agreements Effective upon the consummation of the Redomiciliation, Wave-Delaware entered into indemnification agreements (the “ Indemnification Agreements ”) with each of Wave-Delaware’s directo
2 min readWave Life Sciences (WVE) reported a wider Q2 2026 net loss, up 37.4% to $69.35M, as revenue fell 74% to $2.27M. Cash, cash equivalents and marketable securities were $490.6M as of June 30, 2026, funding operations into Q3 2028. The company also reaffirmed 2026 clinical and regulatory milestones, including obesity and AATD updates.
4 min readWave Life Sciences (NASDAQ: WVE) reported Q2 results for the quarter ended June 30, 2026. The company said it began dosing in the Phase 2a portion of its INLIGHT obesity trial with WVE-007, citing Phase 1 fat reduction without muscle loss and potential infrequent dosing. It also plans Phase 2 studies for WVE-007 with incretins and as post-incretin maintenance, and updated RestorAATion-2 data for WVE-006 in AATD.
2 min readWave Life Sciences Ltd. (WVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2 ) and comorbidities; tri
6 min read
